SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-19-013728
Filing Date
2019-07-26
Accepted
2019-07-26 16:32:06
Documents
3
Period of Report
2019-07-26

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER f6k072619_enlivextherap.htm 6-K 12135
2 UNAUDITED HISTORICAL FINANCIAL INFORMATION FOR ENLIVEX AS OF JUNE 30, 2019 AND D f6k072619ex99-1_enlivex.htm EX-99.1 228962
3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2019 AND DECEMBER 31 f6k072619ex99-2_enlivex.htm EX-99.2 78169
  Complete submission text file 0001213900-19-013728.txt   320506
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 19978375
SIC: 2834 Pharmaceutical Preparations